Cambrian Bioworks raised $1.45 million in seed funding led by the Irani family office to improve its automated molecular diagnostics platforms and expand globally.
Founded in 2020, the Bengaluru-based startup develops automated platforms used in oncology, genomics, and disease testing.
With the recent launch of Manta, their nucleic acid extraction device, Cambrian Bioworks plans to extend its reach by enabling broader access to automated devices for liquid biopsy testing,
Inc42 Daily Brief
Stay Ahead With Daily News & Analysis on India’s Tech & Startup Economy
Biotechnology startup Cambrian Bioworks has secured $1.45 Mn (INR 12 Cr) in a seed funding round led by the Irani family office, along with participation from the company’s cofounder and CEO Vaibhav Hegde.
The Bengaluru-based startup plans to use the fresh capital to scale up its automated molecular diagnostics platforms,bolster R&D efforts, expand team and support international market expansion.
Founded in 2020, by Vaibhav Hegde, Rohit Asil and Raghav Sridhar, Cambrian Bioworks builds automated molecular diagnostic platforms.
The company’s products find applications in oncology, genomics, rare disease testing, and AMR detection. It builds tools for advanced DNA sequencing and molecular diagnostic markets.
“Molecular diagnostics is crucial for precise diagnosis, disease subtyping, and therapy selection in cancer care. This funding marks a significant milestone in our journey.” Hegde said.
This comes four months after Cambrian rolled out nucleic acid extraction platform Manta in April. According to the company, this automated device extracts and purifies nucleic acids, such as DNA, RNA and cell-free DNA (cfDNA) from various clinical samples.
According to IBEF and Statista reports, India’s biotechnology industry was valued at over $92 billion in 2023, with the broader bioeconomy reaching $137 billion.
The sector is poised for significant growth, with projections targeting $150 billion by 2025 and $300 billion by 2030.
This growth trajectory is supported by a robust 17% CAGR, driven by rising demand for Indian vaccines and biopharmaceuticals, government initiatives, and an increasing focus on generics and biosimilars.
Note: We at Inc42 take our ethics very seriously. More information about it can be found here.